Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It’s clearly written in his comp plan. Quite ridiculous to be honest
1Q24 Report (due May 15th or May 20th with extension)
1) Hopefully, it will be the first quarterly issued on time since 1Q22, maintaining Pink Current status (credibility and reputation)
2) Hopefully, it will document receipt of $1.2M of back licensing fees (credibility and reputation)
3) Hopefully, it will document 14 states worth of licensing fees ($210K for quarter) in alignment with 10/24/23 PR. (credibility and reputation)
4) Hopefully, it will document increase from trickle of online sales.
Guys, keep it in the low. If something is really going on in VDRM, it is in your best interest to extend this Zombie for as long as possible. We don’t want to figure out this is a bubble full of $hitt and end up exploding on our faces, on our own watch while being invested
IF and I mean IF the $1.2 million is paid, he(Otiko) will find a way to pay himself all of it.
I should say pay himself back since these funds are coming from another one of his companies.
"02/24 Company received $1.2M of back licensing payments Accounts Receivables"
JMHO
CEO """""Performance"""""????????
10/01/22 Gives HIMSELF new performance package:
$100K plus 20M shares for each year - Not unreasonable in this stock price range, if there was actual performance
One-time bonus of 20M share if stock price reaches $1.00 - Bargain
30% of revenue for any contract he brings up to $1M - Ridiculous
40% of revenue over $2M for any contract he brings - Something well beyond ridiculous
03/28/23 CEO is legitimately owed $118.244K by company
Gives HIMSELF 100M shares. Opening stock price on that day was $0.027. Value of stock to settle $118.244K debt: $2.7 Million. There are not words to come close to describing how ridiculous, over-the-top, insulting and undeserved $2.5M of that is. That stock is still worth $959K at yesterday's close, for $118K debt.
Unfortunately, it is likely a huge indicator of capability that, even with the ridiculous performance clauses triggered if CEO brought in contracts, NONE have ever made it to the company cash flow, even with HIM being the personal beneficiary, not the company, of significant portion of revenue that would result from them.
What have shareholders gotten for the above?
12/22 Started a trickle of online sales
02/24 Company received $1.2M of back licensing payments Accounts Receivables (from his other company) - Must be confirmed in 1Q24 report
The scales are beyond argument, tilted in a certain direction.
Still hoping that a great, very effective product can overcome the humongous drags in other areas, to once, and for all, benefit actual shareholders.
Some can't take the pressure I'm fine because it's NOT over Yes it's been a slow ride But it WILL happen.
The Dr. won't throw in the towel . There is money to be made here enough said.
Guys, I am going to encourage you to stay silent and don’t push too much this company or make any reports to the SEC over this. You might end up opening a can of warms and losing your holdings (If this end up to be a real scam).
Look, it is not morally correct what I am saying but OTCM is full of BS and we do still deal with them. Leave ViaDerma alone, don’t reach them, don’t speculate. MMs are doing the job for them. Do you want your money back like me? Wait for another 0.02-0.05 cents spike and GTFO. It always does such once or twice a year. Be smart and let this shit to continue spreading from the fan around.
I really don’t care if it legit or not. Honestly I don’t want to stay to find out. I see other tickers like IGPK making people money and I have several thousands of dollars stuck in here when I can invest it somewhere else. I ain’t leaving at a loss tho. Even or making a profit, not weak hands
I am to. He announced receipt of $1.2M and that it would be in (1st Qtr) financials, on X, but, with him, it means nothing.
I am very curious to see what receivables have been collected on the next quarterly report.
I use Richardinza@gmail.com . He very regularly ignores emails for longgggg periods of time, very believably because CEO gives him little to nothing, with brief periods of responses, usually after having to be emailed many, many, many times, about reporting, for example. Currently, he is ignoring my requests for management explanation of why official PRs on number of states in state licensing deals does not match the revenue for any quarter in 2023 in financial reports (revenue, of course, is less), after aligning perfectly in 2022.
Never, not once.
Less than 1% they get filed on time.
anyone ever get any replies from ir@viaderma.com ?
I can’t imagine a world where he submits anything on time. He has shown time after time he’s not scared of a yield sign and doesn’t care for the shareholder
I think only thing supporting this share price is the MM is stuck with expensive shares.
You can find all info here. Item 5 is what you are looking for:
https://www.otcmarkets.com/files/OTCPinkGuidelines.docx
I always forget, they’re due 60days after end?
Let’s see if Otiko files the Q1 on time or goes delinquent again!!
The donation what??? OML
We need some help here.!!
MMs game. Today was a bloody day. Crazy. I don’t trust this PPS at all. Not taking chances in here, Otiko could make a merger and I still will walk away when I get even in here. I just want my capital back. I don’t care about this ponzi anymore
Someone has a sense of humor 😀. To get VDRM back to unchanged with minutes to go a trade of "911"
Gosh… Chuckles! These guys are incredible…
I respect your optimism, you guys must be touching bottom that keep thinking this is the week for the supernova!! 😂
History repeats itself, Otiko did it again
could this be the week for an update finally?
Despite of confirmation that this IS NOT A PUMP AND DUMP: This one moves like a Pump and dump one.
I am just saying it as I am seeing it how it behaves…
Back to double digits and not signs of the doc!
Fugazi
I agree, this is not a pump and dump scheme but it is smelling very bad… If it smell and look bad it is definitely…………
The CEO has been in the bathroom and hasn’t come out of it since months. So, you tell me what is this? Not looking good and CEO is M.I.A
Correct this is not a pump and dump. Anyone who is trying to push that BS has never seen one .lol. So far from the truth I am still laughing.!!!
Shhhh… Don’t talk about the IR. There’s someone in here that claims to have direct access to such. Some people in here idolize him. Watch out, I almost got stabbed once from one of them. The friend of my friend! 😂
We have been here before, pump and dump again. Someone is manipulating this well
Did you misplace your rose colored glasses?
The Close info : 1,282,500@.01. well above sub - penny, again. All have good weekend.
No PRs. No tweets. Nothing from them in months and the IR guy never responds to anything either.
This guy has been there for 8 years. https://www.linkedin.com/in/garrettradams
Doesn't look like he's ever closed a deal either. What does he even do?
They need to step up fast!
We will not die, but we will dry, slowly.
Otiko: Me not like him… He did never landed a deal and he never will. He is not a business man, he is a doctor and researcher, he shall stay in his lane and hire a veteran CEO that can bring his bodega into the spotlight
Wow right after this we are now 557,500@.0099. need to drop a beginning "0" but a start.
Did we die and no notice put out ??
This will cut expenses & help share holders
Dr. using his garage 2 bottle & package 24/7
Maybe he is negotiating a MEGA Deal for 20 million bottles…… I’m pretty sure he wants the bonuses when the Share Price hits $1.00 per share
it is neither weird or scary! no press means no interest period! the company IR and blame the CEO have done a terrible job at keeping shareholders in the know
Today it looks more weird than scary. Very strange ViaDerma PPS
over 1.5 million bid just wish the price was .095 !!!!
Need a bush beater.
Followers
|
619
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
74597
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
We are developing products in the following fields of use;
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Treats symptoms of Influenza which is a$4B/ year global market: Common
Diabetic foot wounds.
Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.
Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.
The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.
CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.
CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
"What is Intellectual Property?" - A Publication by the World Intellectual Property Organization -
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |